BIO Welcomes New Industrial & Environmental Section Members

BIO today announced six companies have joined the Industrial & Environmental Section in the past year. The announcement was made following BIO’s Industrial & Environmental Section member meeting and election of governing board officers at the 2016 BIO International Convention in San Francisco. 

BIO Elects New Board Officers and Members

BIO is pleased to announce the election of two new Board Officers, several new Section Governing Board Chairs, and 21 new members of its Board of Directors, all voted upon at this year’s 2016 BIO International Convention.

Office of the National Coordinator for Health Information Technology; Medicare Access and CHIP Reauthorization Act of 2015; Request for Information (RFI) Regarding Assessing Interoperability for MACRA

The Biotechnology Innovation Organization (BIO) is pleased to submit the following comments in response to the Request for Information (RFI) Regarding Assessing Interoperability for MACRA (the “RFI”).1 BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.

BIO Brings Airgas® Products & Services to BIO Members

Washington, D.C. (June 2, 2016) – The Biotechnology Innovation Organization (BIO) has announced a new partnership with Airgas, an Air Liquide company and one of the nation’s leading suppliers of industrial, medical, and specialty gases, and related products, to add cylinder gases, bulk gases, dry ice and related supplies to the BIO Business Solutions® offerings. 

GM Crops Help Ensure Global Food Security Through Higher Crop Yields

Farmers around the world who use seeds improved with biotechnology continue to benefit economically while improving the environmental sustainability of their farming operations according to the report “GM Crops: Global Socio-Economic and Environmental Impacts 1996-2014” released by PG Economics.

2016 BIO International Convention Adds More Events to Already Robust Program

BIO announced that two additional Fireside Chats will be added to the 2016 BIO International Convention program. Also announced, were the winners of its “Future Makers in Biotech” contest in which individuals were nominated by their peers for vision, innovation, and advancements in biotechnology. 

BIO Business Solutions Extends Agreement with VWR

Washington, D.C. (June 1, 2016) – Today, the Biotechnology Innovation Organization (BIO) announced a new agreement with VWR to provide members with laboratory supplies, equipment and chemicals through June 2023.

Ambassador Darci Vetter to Keynote Food and Ag Track at 2016 BIO International Convention

BIO has officially announced that Ambassador Darci Vetter, Chief Agricultural Negotiator of the Office of the U.S. Trade Representative, will deliver the keynote address during the Food and Agriculture track at the 2016 BIO International Convention.  BIO 2016 will be held June 6-9, 2016 in San Francisco, California at the Moscone Center.

BIO Applauds Reps. Sean Duffy and John Carney for Introducing the Corporate Governance Reform and Transparency Act

Today, the Biotechnology Innovation Organization (BIO) applauds Reps. Sean Duffy (R-WI) and John Carney (D-DE) for introducing the Corporate Governance Reform and Transparency Act. 

BIO Releases Largest Study Ever on Clinical Development Success Rates

Today, the Biotechnology Innovation Organization (BIO) released the largest study ever of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success.